1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €106.65 (+9.95%). The median is €107.89 (+11.23%).
| Buy |
11 |
| Hold |
3 |
| Sell |
0 |
News Go to news feed
Monopar names head of Medical Affairs and reports ALXN1840 presentations at liver congress
Monopar appoints Dr. Jeffrey D. Kent as of September 1, 2026, to executive vice president and head of Medical Affairs. Two abstracts on ALXN1840, the late-stage development program for the treatment of Wilson disease, were accepted for presentations at AASLD “The Liver Meeting 2026,” including an oral presentation of the phase 3 results on November 8. ALXN1840 met the primary endpoint of copper mobilization over 48 weeks in the approval-relevant phase 3 study. » More on de.investing.com
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -4.66M | 123.65% |
| EBITDA | -4.66M | 123.65% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €657.53M |
Number of shares | 6.7M |
52-week high/low | €107.73 - €27.65 |
| Dividends | No |
Beta | 1.51 |
P/E ratio | -48.60 |
PEG ratio | 1.70 |
P/B ratio | 7.42 |
P/S ratio | 0.00 |
Company profile
| Name | Monopar Therapeutics Inc |
| CEO | Chandler D. Robinson |
| Employees | 22 |
Discover assets
Shareholders of Monopar Therapeutics Inc also invest in the following assets
